STAT+: Amgen’s rheumatoid arthritis drug Enbrel targeted for first-in-the-nation price limit in Colorado
Colorado moves to cap the price of Etanercept, an autoimmune drug sold by Amgen under the brand name Enbrel, in drive to lower prescription drug prices.
WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription drug costs.
In a first-in-the-nation move, a state board voted to create a payment limit for a widely prescribed Amgen drug used to treat arthritis, a step that may usher in a new era in which state governments take more aggressive action to control the cost of prescription medicines.
The drug, called Enbrel, costs insurers an average of $46,772 per patient per year, according to 2022 data from the state’s all-payer claims database. The state board evaluated two other drugs so far, but Enbrel was the first the board deemed unaffordable for Colorado patients. The board has not yet begun discussions about what the payment limit could be.
What's Your Reaction?
